Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


At J&J, Q3 Pharma Performance Is Up, Rest of Business Is Down

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts were disappointed in J&J's overall results, but the pharma sector performed well, driven by Remicade and new product sales.

You may also be interested in...

Eli Lilly, J&J, Novartis: Emerging Markets Earnings Roundup (Part 1 of 2)

Restructuring and diversification was the theme of third quarter earnings calls, as both American and European Big Pharma companies continued to shift resources into emerging markets.

J&J vs. Merck: What Might A Remicade Settlement Look Like?

Analysts say Merck has a good chance of prevailing in arbitration over J&J's agreement with Schering to co-distribute Remicade but that the two parties may opt to settle.

J&J Pharma Hit By EU Price Cuts, Weaker Euro

Hit from EU pricing cuts is estimated at about $200 million in 2010.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts